3 Reasons to Buy CRISPR Therapeutics Stock

The value of Chinese Biotech

A handpicked article read aloud from the latest issue of The Economist

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow proc

AI Stocks Look Expensive. These 3 ETFs Could Help Investors Stay in the Game.

CRISPR’s next act: the companies editing the epigenome to treat disease

A feature in Nature reports how a handful of start-up firms are testing therapies that target specific epigenetic markers to treat everythin

VYNE Therapeutics declares special cash dividend with Yarrow Bioscience merger

See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F